

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
60726-AZU.S. Serial No.
10/776,442INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant:
Moses Rodriguez and Daren UreFiling Date:
February 10, 2004Group Art Unit
1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CYW	1	4 1 2 9 6 6 6	12/12/78	Wizerkaniuk;			
	2	4 5 9 4 4 0 9	6/10/86	Hayashi et al.;			
	3	5 9 6 5 6 0 0	10/12/99	Sato et al.;			
	4	6 0 2 4 9 8 1	2/15/00	Khankari et al.;			
	5	6 1 6 2 8 0 0	12/19/00	Dolle et al.;			
	6	6 5 1 4 9 3 8	2/4/03	Gad et al.;			
	7	6 6 2 0 8 4 7	9/16/03	Konfino et al.;			
	8	6 8 0 0 2 8 5	10/5/04	Rodriguez et al.;			
	9	6 8 0 0 2 8 7	10/5/04	Gad et al.;			
	10	6 8 4 4 3 1 4	1/18/05	Eisenbach-Schwartz et al.;			
	11	6 9 3 9 5 3 9	9/6/05	Konfino et al.;			
CYW	12	7 0 2 2 6 6 3	4/4/06	Gilbert et al.;			

		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
CYW	37	0 3 7 8 2 4 6	6/18/86	Europe;			
CYW	38	3 9 3 0 7 3 3	3/28/91	Germany;			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CYW	48	Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94, 10821-10826;
	49	Aharoni, et al., "Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", <u>Neurology</u> , 1997, Vol. 48, No. 3, A422 (Abstract);
	50	Aharoni, et al., "Bystander Suppression of Experimental Autoimmune Encephalomyelitis by T Cell Lines and Clones of the Th2 Type Induced by Copolymer 1", <u>J. Neuroimmunol.</u> , 1998, 91(1-2), 135-146;
	51	Bodanszky, M., "Principles of Peptide Synthesis", Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, pp. 118-229;
	52	Bornstein, et al., "Rationale For Immunomodulating Therapies of Multiple Sclerosis: Clinical Trial Design In Multiple Sclerosis Therapy", <u>Neurol.</u> , 1988, Vol. 38 (Suppl.2), pp. 80-81;
	53	Bornstein, M., "Clinical Experience: Hopeful Prospects In Multiple Sclerosis", <u>Hospital Practice</u> , 1992, Vol. 27, No. 5, pp. 135-158;
	54	Cazzato, et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit'a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina. October 1999, 90(10), 538-544
	55	Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", <u>The Journal of Immunology</u> , 2000, 165, 7300-7307;
	56	Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract);
CYW	57	Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group", <u>Neurology</u> , 45(7), 1268 (Abstract);

EXAMINER /Chang-Yu Wang/ DATE CONSIDERED 10/04/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Inventors: Moses Rodriguez and Dare Ure
Serial No.: 10/776,442
Filed: February 10, 2004
Exhibit A

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant: Moses Rodriguez and Daren Ure	
		Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CYW	13	7 0 3 3 5 8 2	4/25/06	Yong, et al.;		
	14	7 0 7 4 5 8 0	7/22/06	Gad et al.;		
	15	20 02 00 37 8 4 8	3/28/02	Eisenbach-Schwartz et al.;		
	16	20 02 01 15 1 0 3	8/22/02	Gad et al.;		
	17	20 02 01 07 3 8 8	8/8/02	Vandenbark;		
	18	20 02 00 77 2 7 8	6/20/02	Yong et al.;		
	19	20 03 01 70 7 2 9	9/11/03	Klinger;		
	20	20 04 00 06 0 2 2	1/8/04	Strominger et al.;		
	21	20 04 01 06 5 5 4	6/3/04	Konfino et al.;		
	22	20 05 00 14 6 9 4	1/20/05	Yong et al.;		
	23	20 05 00 19 3 2 2	1/27/05	Rodriguez et al.;		
CYW	24	20 05 00 38 2 3 3	2/17/05	Gad et al.;		

FOREIGN PATENT DOCUMENTS

FORN DISSENT DOCUMENTS														
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
CYW	39	0	2	5	4	4	9	6	8/27/96	New Zealand;				
CYW	40	0	3	3	6	6	9	0	1/12/98	New Zealand;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CYW	58	Korczyn, et al., "Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel", <u>J. Neurol.</u> , 1996, Vol. 243 (Suppl. 1): S23-S26;
	59	Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases", Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, URL: http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM ;
	60	Merck Manual of Diagnosis and Therapy, <u>Merck Research Laboratories</u> , Whitehouse Section, N.J., 17 th Ed., 1999, pp. 1300-1303, pp. 1312-1317;
	61	Pharmacia Biotech Directory, 1996, pp. 340-341;
	62	Physician's Desk Reference, 2000, Medical Economics Co. Inc., Montvale, NJ, 3115;
	63	Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", <u>Annu. Rev. Immunol.</u> , 1991, 9, 527-565;
	64	Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", <u>Department of Neurological Sciences, University of Rome, La Sapienza</u> 1991, 72 (Abstract);
	65	Sela, et al., "Synthetic Approaches To Vaccines For Infectious And Autoimmune Diseases", <u>Vaccine</u> , 1992, Vol. 10, No. 14, pp. 991-999;
CYW	66	Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", <u>Ann. Neurol.</u> , 1994, 36, 114-115

EXAMINER /Chang-Yu Wang/ DATE CONSIDERED 10/04/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614	
U.S. PATENT DOCUMENTS								
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
	CYW 25	20 05 01 70 0 0 4	8/4/05	Rosenberger et al.;				
	26	20 05 01 71 2 8 6	8/4/05	Konfino et al.;				
	27	20 05 02 56 0 4 6	11/17/05	Gad et al.;				
	28	20 06 00 52 5 8 6	3/9/06	Dolitzky;				
	29	20 06 01 22 1 1 3	6/8/06	Pinchasi et al.;				
	30	09 8 8 5 2 2 7	6/20/01	Rodriguez and Ure;				
	31	10 5 4 7 4 6 3	8/30/05	Pinchasi et al.;				
	32	10 5 5 6 4 5 4	11/17/05	Vollmer;				
	33	10 5 7 7 5 8 8	4/27/06	Rosenberger et al.;				
	34	11 2 2 8 8 5 0	9/14/05	Schwartz et al.;				
	35	11 3 3 6 2 5 1	1/20/06	Dolitzky;				
	CYW 36	11 3 7 3 7 9 4	3/9/06	Pinchasi;				
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
	CYW 41	1 6 9 0 3 6 8	8/20/95	Russia;				
	42	1 4 6 9 8 2 6	11/20/95	Russia;				
	43	0 9 8 0 2 1 4	9/29/99	South Africa;				
	44	1 1 8 2 0 5 1	9/30/85	Soviet Union;				
	45	1 6 6 4 8 4 5	7/23/91	Soviet Union;				
	46	03 0 4 8 7 3 5	6/12/03	WO;				
CYW 47	06 0 5 0 1 2 2	5/11/06	WO;					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
CYW	67	Teva, et al., "Copolymer-1 Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , 1998, Vol. 23, No. 2, pp. 213-214;						
CYW	68	Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Isr. J. Med. Sci.</u> , 1975, <u>11</u> , 1388 (Abstract);						
CYW	69	Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", <u>Journal of Neuroimmunology</u> , 2001, 119, 137-144;						
EXAMINER /Chang-Yu Wang/			DATE CONSIDERED 10/04/2006					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								